Literature DB >> 31645103

A Hierarchical Peptide-Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Protein-Protein Interaction.

Jin Yan1, Siqi Yan2, Peng Hou2, Wuyuan Lu3, Peter X Ma4, Wangxiao He5, Bo Lei1.   

Abstract

Intracellular protein-protein interactions (PPIs) are a vital and yet underexploited class of therapeutic targets for their crucial roles in cellular processes and involvement in disease initiation and progression. Although some successful chemistry and nanotechnologies have been introduced into peptide PPI modulators to allow cell and tissue permeability, significant challenges remain with regard to the efficient and precise modulation of PPIs within specific cells of diseased tissues, such as solid tumors. Herein, an intratumoral transformable hierarchical framework, termed iPLF, was fabricated via a two-step self-assembly between peptides and lanthanide-doped nanocrystals. In this proof-of-concept study, using NanoEL effect, TME response, and tumor marker targeting, iPLF in vivo delivered the p53-MDM2 modulator DPMI into tumor cells and β-catenin-Bcl9 modulator Bcl9p into tumor stem cells. This crafted programmed nanomedicine with triple-stage delivery and responsiveness accurately modulated the specific intracellular protein-protein interactions, resulting in the suppression of tumor growth and metastasis in vivo, while maintaining a highly favorable safety profile. iPLF reached the goal of accurate, potent, and hazard-free intracellular PPI modulation, thereby providing a means to improve current knowledge of PPI networks and a novel therapeutic strategy for a great variety of diseases.

Entities:  

Keywords:  Intracellular protein−protein interactions; cancer therapy; nanotechnology; peptide drug; stimuli response

Year:  2019        PMID: 31645103     DOI: 10.1021/acs.nanolett.9b03028

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  7 in total

1.  Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors.

Authors:  Weiming You; Fang Ma; Zhang Zhang; Jin Yan
Journal:  Pharmaceutics       Date:  2022-06-20       Impact factor: 6.525

2.  Restorative biodegradable two-layered hybrid microneedles for melanoma photothermal/chemo co-therapy and wound healing.

Authors:  Yue Shan; Bowen Tan; Min Zhang; Xi Xie; Jinfeng Liao
Journal:  J Nanobiotechnology       Date:  2022-05-19       Impact factor: 9.429

3.  A Bionic-Homodimerization Strategy for Optimizing Modulators of Protein-Protein Interactions: From Statistical Mechanics Theory to Potential Clinical Translation.

Authors:  Jin Yan; Xiaoqiang Zheng; Weiming You; Wangxiao He; Guang-Kui Xu
Journal:  Adv Sci (Weinh)       Date:  2022-02-15       Impact factor: 16.806

4.  Turing miRNA into infinite coordination supermolecule: a general and enabling nanoengineering strategy for resurrecting nuclear acid therapeutics.

Authors:  Liya Li; Wangxiao He; Weiming You; Jin Yan; Wenjia Liu
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

5.  Turing milk into pro-apoptotic oral nanotherapeutic: De novo bionic chiral-peptide supramolecule for cancer targeted and immunological therapy.

Authors:  Wangxiao He; Zhang Zhang; Wenguang Yang; Xiaoqiang Zheng; Weiming You; Yu Yao; Jin Yan; Wenjia Liu
Journal:  Theranostics       Date:  2022-02-21       Impact factor: 11.556

Review 6.  Nanomedicines Targeting Metabolism in the Tumor Microenvironment.

Authors:  Mengdi Ren; Xiaoqiang Zheng; Huan Gao; Aimin Jiang; Yu Yao; Wangxiao He
Journal:  Front Bioeng Biotechnol       Date:  2022-08-05

7.  Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis.

Authors:  Weinan Guo; Zhenjie Wu; Jianru Chen; Sen Guo; Weiming You; Sijia Wang; Jinyuan Ma; Huina Wang; Xiangxu Wang; Hao Wang; Jingjing Ma; Yuqi Yang; Yangzi Tian; Qiong Shi; Tianwen Gao; Xiuli Yi; Chunying Li
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.